Physician profile
Robert A Lafyatis
NPI 1902896822
$88,436.05
in general payments reported to CMS, 2019-2025
16 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $14K · 2021: $8,730 · 2022: $4,860 · 2023: $27K · 2024: $9,423 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,506 · Travel and Lodging: $1,191 · Food and Beverage: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $39,057.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,505.58 |
| Travel and Lodging | $1,191.47 |
| Food and Beverage | $506.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $44,417.55 | 2019-2025 | Ofev |
| Abbvie INC. | $13,891.63 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $10,395.00 | 2022-2023 | |
| Kyowa Kirin Co., LTD | $6,027.07 | 2019 | |
| Boehringer Ingelheim International Gmbh | $5,700.00 | 2020-2021 | |
| Genentech, INC. | $4,375.00 | 2020-2024 | |
| Biogen, INC. | $1,305.00 | 2021 | |
| Pfizer INC. | $1,000.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $800.00 | 2024 | |
| Kyowa Kirin, INC. | $400.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.80 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lafyatis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.